All of this seems to be linked to examining Elmiron in clinical trials and to also potentially help with NHMRC funding perhaps, since no company will want to fund OA trials with Elmiron due to the safety issues, lack of bio availability and the absence of meaningful IP. So my guess is the timing of the publications are the result of NHMRC applications to help fund the clinical trials.
This is on the back of the following article shared by Iken, which shows when you consider a historical control for OA that Elmiron doesn't work based on their treatment protocol: https://www.sciencedirect.com/science/article/pii/S2665913123000109
The following trial was registered two years ago, which it seems they have yet to find funding for:https://trialsearch.who.int/?TrialID=ACTRN12621000654853
Arthropharm have an interest presumably because they would supply Elmiron. I note in the review article that they mention NGF, but fail to provide a reference. Maybe they were referring to the following: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0222602.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-3630
-
- There are more pages in this discussion • 558 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
30.5¢ |
Change
-0.005(1.61%) |
Mkt cap ! $108.4M |
Open | High | Low | Value | Volume |
31.0¢ | 31.5¢ | 30.0¢ | $90.23K | 289.7K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 6715 | 30.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.0¢ | 58126 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 6715 | 0.300 |
2 | 12617 | 0.295 |
7 | 100888 | 0.290 |
4 | 47143 | 0.285 |
4 | 112550 | 0.280 |
Price($) | Vol. | No. |
---|---|---|
0.310 | 58126 | 6 |
0.315 | 12000 | 1 |
0.320 | 45583 | 3 |
0.325 | 60366 | 5 |
0.330 | 126311 | 5 |
Last trade - 11.21am 15/07/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |